Study Summary
This trial found that VTE can be the earliest sign of cancer and that identifying occult cancers at the time of VTE diagnosis may lead to significant improvement of patients' care.
- Blood Clot
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 7 Secondary · Reporting Duration: At 1 year of follow-up
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
2 Treatment Groups
Limited cancer screening
1 of 2
Limited cancer screening + FDG PET/CT
1 of 2
Active Control
Experimental Treatment
1276 Total Participants · 2 Treatment Groups
Primary Treatment: Limited cancer screening + FDG PET/CT · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:- Carrier, Marc, Alejandro Lazo-Langner, Sudeep Shivakumar, Vicky Tagalakis, Ryan Zarychanski, Susan Solymoss, Nathalie Routhier, et al.. 2015. “Screening for Occult Cancer in Unprovoked Venous Thromboembolism”. New England Journal of Medicine. Massachusetts Medical Society. doi:10.1056/nejmoa1506623.
- van Es, Nick, Grégoire Le Gal, Hans-Martin Otten, Philippe Robin, Andrea Piccioli, Ramón Lecumberri, Luis Jara-Palomares, et al.. 2017. “Screening for Occult Cancer in Patients with Unprovoked Venous Thromboembolism”. Annals of Internal Medicine. American College of Physicians. doi:10.7326/m17-0868.
- Robin, Philippe, Pierre-Yves Le Roux, Benjamin Planquette, Sandrine Accassat, Pierre-Marie Roy, Francis Couturaud, Nadia Ghazzar, et al.. 2016. “Limited Screening with Versus Without 18f-fluorodeoxyglucose PET/CT for Occult Malignancy in Unprovoked Venous Thromboembolism: An Open-label Randomised Controlled Trial”. The Lancet Oncology. Elsevier BV. doi:10.1016/s1470-2045(15)00480-5.
- Robin, Philippe, Pierre-Yves Le Roux, Benjamin Planquette, Sandrine Accassat, Pierre-Marie Roy, Francis Couturaud, Nadia Ghazzar, et al.. 2016. “Limited Screening with Versus Without 18f-fluorodeoxyglucose PET/CT for Occult Malignancy in Unprovoked Venous Thromboembolism: An Open-label Randomised Controlled Trial”. The Lancet Oncology. Elsevier BV. doi:10.1016/s1470-2045(15)00480-5.
- Carrier, Marc, Alejandro Lazo-Langner, Sudeep Shivakumar, Vicky Tagalakis, Ryan Zarychanski, Susan Solymoss, Nathalie Routhier, et al.. 2015. “Screening for Occult Cancer in Unprovoked Venous Thromboembolism”. New England Journal of Medicine. Massachusetts Medical Society. doi:10.1056/nejmoa1506623.
- van Es N, Le Gal G, Otten HM, Robin P, Piccioli A, Lecumberri R, Jara-Palomares L, Religa P, Rieu V, Rondina M, Beckers MM, Prandoni P, Salaun PY, Di Nisio M, Bossuyt PM, Buller HR, Carrier M. Screening for Occult Cancer in Patients With Unprovoked Venous Thromboembolism: A Systematic Review and Meta-analysis of Individual Patient Data. Ann Intern Med. 2017 Sep 19;167(6):410-417. doi: 10.7326/M17-0868. Epub 2017 Aug 22.
- 2020. "Screening for Occult Malignancy in Patients With Unprovoked Venous Thromboembolism". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04304651.
Frequently Asked Questions
In how many locales is this investigation functioning?
"Numerous locations across Canada are recruiting participants, including the University of Calgary in Calgary, McMaster University in Hamilton, and the University of Manitoba in Winnipeg. Additionally, there are several other sites where patients may be enrolled." - Anonymous Online Contributor